Stoke Therapeutics (STOK) Cash from Investing Activities (2018 - 2026)

Stoke Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $50.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 271.88% year-over-year to $50.7 million; the TTM figure through Mar 2026 stood at -$149.8 million (down 44.22% YoY), while the FY2025 annual figure was -$186.8 million, down 73.82% from the prior year.
• Cash from Investing Activities was $50.7 million for Q1 2026 at Stoke Therapeutics, up from -$61.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $67.3 million in Q3 2022 to a low of -$148.5 million in Q2 2025.
• Historically, Cash from Investing Activities has averaged -$10.8 million across 5 years, with a median of $10.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 66459.8% in 2022, then surged 15977.4% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at $22.5 million in 2022, then plunged by 34.32% to $14.8 million in 2023, then sank by 94.46% to $819000.0 in 2024, then sank by 7555.56% to -$61.1 million in 2025, then surged by 183.02% to $50.7 million in 2026.
• The last three Cash from Investing Activities figures came in at $50.7 million (Q1 2026), -$61.1 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.